Cargando…
A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study
INTRODUCTION: Human studies on low-dose resveratrol are scarce. This study aims to evaluate the safety, tolerability, and efficacy of an oral preparation of resveratrol, glucose, and malate (RGM) in slowing the progression of Alzheimer's disease (AD). METHODS: Thirty-nine subjects with mild to...
Autores principales: | Zhu, Carolyn W., Grossman, Hillel, Neugroschl, Judith, Parker, Susan, Burden, Amanda, Luo, Xiaodong, Sano, Mary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240843/ https://www.ncbi.nlm.nih.gov/pubmed/30480082 http://dx.doi.org/10.1016/j.trci.2018.09.009 |
Ejemplares similares
-
Prevalent, persistent, and impairing: Longitudinal course and impact of apathy in Alzheimer's disease
por: Grossman, Hillel T., et al.
Publicado: (2022) -
Role of RGM coreceptors in bone morphogenetic protein signaling
por: Halbrooks, Peter J, et al.
Publicado: (2007) -
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016) -
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
por: Turner, R. Scott, et al.
Publicado: (2015) -
A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)